ArticlePloS one2021

Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.

Caroline Schmidbauer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.